Fresenius Medical Care US Finance III, Inc., a prominent entity within the healthcare sector, is headquartered in the United States. Established as part of Fresenius Medical Care AG & Co. KGaA, the company focuses on providing comprehensive renal care and dialysis services, catering to patients across various regions in the US. Founded in the early 1990s, it has achieved significant milestones, including advancements in dialysis technology and patient care. The company’s core offerings include innovative dialysis products and services, which are distinguished by their commitment to improving patient outcomes and enhancing quality of life. With a strong market position, Fresenius Medical Care US Finance III, Inc. is recognised for its dedication to excellence in renal care, making it a leader in the industry.
How does Fresenius Medical Care US Finance III, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Financial Intermediation industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fresenius Medical Care US Finance III, Inc.'s score of 56 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fresenius Medical Care US Finance III, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Fresenius Medical Care AG, which may influence its climate commitments and performance metrics. While there are no documented reduction targets or climate pledges specific to Fresenius Medical Care US Finance III, Inc., it is important to note that any climate initiatives or targets would likely be inherited from its parent company, Fresenius Medical Care AG. This includes potential commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks, although specific details on these initiatives are not provided. As a subsidiary, Fresenius Medical Care US Finance III, Inc. may align its climate strategies with those of Fresenius Medical Care AG, which is expected to have established industry-standard practices for managing carbon emissions and addressing climate change. However, without specific data or targets, the company's individual climate impact remains unclear.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000.0 | 
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000.0 | 
Fresenius Medical Care US Finance III, Inc.'s Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2023, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 17640922% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fresenius Medical Care US Finance III, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.